A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
Open Access
- 17 February 2021
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-12
Abstract
The four-dengue virus (DENV) serotypes infect several hundred million people annually. For the greatest safety and efficacy, tetravalent DENV vaccines are designed to stimulate balanced protective immunity to all four serotypes. However, this has been difficult to achieve. Clinical trials with a leading vaccine demonstrated that unbalanced replication and immunodominance of one vaccine component over others can lead to low efficacy and vaccine enhanced severe disease. The Laboratory of Infectious Diseases at the National Institutes of Health has developed a live attenuated tetravalent DENV vaccine (TV003), which is currently being tested in phase 3 clinical trials. Here we report, our study to determine if TV003 stimulate balanced and serotype-specific (TS) neutralizing antibody (nAb) responses to each serotype. Serum samples from twenty-one dengue-naive individuals participated under study protocol CIR287 (ClinicalTrials.gov NCT02021968) are analyzed 6 months after vaccination. Most subjects (76%) develop TS nAbs to 3 or 4 DENV serotypes, indicating immunity is induced by each vaccine component. Vaccine-induced TS nAbs map to epitopes known to be targets of nAbs in people infected with wild type DENVs. Following challenge with a partially attenuated strain of DENV2, all 21 subjects are protected from the efficacy endpoints. However, some vaccinated individuals develop post challenge nAb boost, while others mount post-challenge antibody responses that are consistent with sterilizing immunity. TV003 vaccine induced DENV2 TS nAbs are associated with sterilizing immunity. Our results indicate that nAbs to TS epitopes on each serotype may be a better correlate than total levels of nAbs currently used for guiding DENV vaccine development.Keywords
Funding Information
- Bill and Melinda Gates Foundation (AI107731)
This publication has 52 references indexed in Scilit:
- Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and NeutralizationCell Reports, 2018
- Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4Scientific Reports, 2017
- Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and VaccinationJournal of Virology, 2017
- The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge modelScience Translational Medicine, 2016
- Dengue human infection models to advance dengue vaccine developmentVaccine, 2015
- Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trialThe Lancet, 2014
- Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval between Infections and Study YearPLOS Neglected Tropical Diseases, 2013
- Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profilesVaccine, 2013
- The global distribution and burden of dengueNature, 2013
- In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus InfectionPLOS Neglected Tropical Diseases, 2011